Patrick Daly

Cancer Nursing Today nonprod

Ruxolitinib is an oral inhibitor of Janus kinase 1 (JAK1) and JAK2 that is approved for patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (cGVHD) who have failed at least 2 prior lines of therapy. Researchers, led by Jennifer White, sought to expand available data on real-world ruxolitinib treatment.They reviewed outcomes of heavily pretreated patients with cGVHD who received ruxolitinib and found that roughly half of patients responded at months 6 and 12, and many patients were able to completely taper off prednisone at 1 year. Their findings were published in Transplantation and Cellular Therapy.<h3>Real-world Evidence Supports Efficacy of Ruxolitinib</h3>This retrospective study included 115 patients with steroid-refractory cGVHD who previously failed systemic therapies from 5 transplant centers. Authors noted 60% of the population had severe cGVHD and 82% (n=96) had received 3 or more prior lines of therapy before <a href="https://medlineplus.gov/druginfo/meds/a612006.html">ruxolitinib</a>. Clinical benefit was defined by a combination of objective response rate (ORR) and steroid use reduction.According to the authors, the ORR at 3, 6, and 12 months was 48.6%, 54.9%, and 48.5%, respectively, and a clinical benefit was identified in 58.7%, 64.8%, and 60.6% of patients at the same time points. In addition, 37.9% of the patients were able to taper prednisone to a daily dose &lt;0.1 mg/kg at 1 year. Failure-free survival at 12 months was 64.6% (95% CI, 54.1-73.2).The researchers also reported that patients with severe cGVHD had greater risk of failure due to therapy switch, and patients with a pretransplant hematopoietic cell transplantation comorbidity index score &ge;3 exhibited high failure due to increasing nonrelapse mortality risk.&ldquo;This study demonstrates the therapeutic efficacy of ruxolitinib for cGVHD in a heavily pretreated real-world population,&rdquo; the authors summarized.Read More <a href="https://cancernursingtoday.com/page/gvhd">Recent Research on Graft-Versus-Host Disease</a>

Real-world Cohort of Ruxolitinib for cGVHD

GVHD

Real-world data showed that ruxolitinib was effective in a population of heavily pretreated patients with chronic graft-versus-host disease. 

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe